文献速递结核与非结核分枝杆菌

药物基因组学检测指导异烟肼分层给药治疗活动性结核的成本效果

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究构建决策树模型,评估在巴西、南非和印度对药物敏感结核患者开展异烟肼药物基因组学指导治疗(PGT)的终身成本与收益。PGT模拟降低慢乙酰化者的异烟肼毒性并减少快乙酰化者的治疗失败。结果显示PGT在三国的增量成本效果比均低于人均GDP,具有成本效果。

要点

  • PGT在巴西、南非和印度每获得1个QALY的增量成本分别为476、1780和546美元。
  • 概率敏感性分析中,三国99%的模拟结果低于人均GDP。
  • 单因素敏感性分析显示成本效果对所有输入参数稳健。

核心结论

  • 异烟肼药物基因组学指导治疗可改善药物敏感结核患者的健康结局,在巴西、南非和印度具有成本效果。

研究设计与样本

  • 决策树模型,项目终身成本与收益,针对巴西、南非和印度的药物敏感结核患者。
  • PGT模拟降低慢NAT2乙酰化者的异烟肼毒性并减少快乙酰化者的治疗失败。
  • 基因分型检测成本假设与GeneXpert检测相同。

主要发现

  • 单因素敏感性分析显示成本效果对所有输入参数稳健。
  • 概率敏感性分析中,三国99%的模拟结果低于人均GDP。

临床怎么用

  • 在巴西、南非和印度等资源有限地区,异烟肼PGT可能作为改善结核治疗结局的成本效果策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is marked interindividual variability in metabolism and resulting toxicity and effectiveness of drugs used for tuberculosis treatment. For isoniazid, mutations in the N-acetyltransferase 2 (NAT2) gene explain >88% of pharmacokinetic variability. However, weight-based dosing remains the norm globally. The potential clinical impact and cost-effectiveness of pharmacogenomic-guided therapy (PGT) are unknown. METHODS: We constructed a decision tree model to project lifetime costs and benefits of isoniazid PGT for drug-susceptible tuberculosis in Brazil, South Africa, and India. PGT was modeled to reduce isoniazid toxicity among slow NAT2 acetylators and reduce treatment failure among rapid acetylators. The genotyping test was assumed to cost the same as the GeneXpert test. The main outcomes were costs (2018 US dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS: In Brazil, PGT gained 19 discounted life-years (23 QALYs) and cost $11 064 per 1000 patients, a value of $476 per QALY gained. In South Africa, PGT gained 15 life-years (19 QALYs) and cost $33 182 per 1000 patients, a value of $1780 per QALY gained. In India, PGT gained 20 life-years (24 QALYs) and cost $13 195 per 1000 patients, a value of $546 per QALY gained. One-way sensitivity analyses showed the cost-effectiveness to be robust to all input parameters. Probabilistic sensitivity analyses were below per capita gross domestic product in all 3 countries in 99% of simulations. CONCLUSIONS: Isoniazid PGT improves health outcomes and would be cost-effective in the treatment of drug-susceptible tuberculosis in Brazil, South Africa, and India.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rens NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, et al. Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. Clin Infect Dis. 2020. PMID: 31905381. doi:10.1093/cid/ciz1212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。